Many factors, including disease severity or activity and glucocorticoid treatment, which accelerates bone loss, could influence the effect of anti-TNF agents on bone mass in RA patients [146,187,194,195], and explain the discrepancies in these reported outcomes. This evidence concerns the gene TNF and rheumatoid arthritis.